P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model
Our focus is on developing a product with significant potential for treating radiation-induced fibrosis. Disitertide has shown considerable promise in preclinical studies, effectively inhibiting TGF-β signaling, a key driver of fibrosis. For instance, Cruz-Morande et al (PMID: 35448191) demonstrated remarkable muscle antifibrotic effects of the peptide in animal models exposed to radiation. It reduced collagen […]
A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury
Our focus lies in developing a peptide with scientifically validated potential to transform the treatment of fibrosis and related conditions. This scientific foundation underscores our dedication to translating cutting-edge discoveries into impactful solutions for patients worldwide. This peptide, was identified through groundbreaking research, showcases exceptional activity in inhibiting key pathways associated with fibrotic diseases, highlighting […]
Transforming growth factor beta (TGF-β) activity in immuno-oncology studies
Besides its well-known roles in cancer, fibrosis, and cardiovascular disease, TGF-β has gained increasing importance in the treatment and indications of immune and autoimmune diseases in recent years. This publication (PMID: 32178817) discusses the significance of quantifying the activity of Transforming Growth Factor Beta (TGF-β) in various biological contexts, particularly in immuno-oncology studies. Measuring TGF-β […]
